B. Metzler seel. Sohn & Co. AG Has $26.01 Million Stake in Zoetis Inc. $ZTS

Key Points

• B. Metzler seel. Sohn & Co. AG has reduced its stake in Zoetis Inc. by 23.1%, now holding 157,961 shares valued at approximately $26 million.
• Other institutional investors have also adjusted their positions, with Guggenheim Capital LLC increasing its stake by 11.0% to own 269,436 shares valued at $44 million.
• Zoetis reported earnings of $1.76 per share for the last quarter, surpassing analyst expectations and showing a revenue increase of 4.2% year-over-year.

B. Metzler seel. Sohn & Co. AG cut its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 23.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 157,961 shares of the company's stock after selling 47,337 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Zoetis were worth $26,008,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Guggenheim Capital LLC raised its position in shares of Zoetis by 11.0% in the 1st quarter. Guggenheim Capital LLC now owns 269,436 shares of the company's stock valued at $44,363,000 after buying an additional 26,675 shares in the last quarter. CreativeOne Wealth LLC raised its position in shares of Zoetis by 9.0% in the 1st quarter. CreativeOne Wealth LLC now owns 16,053 shares of the company's stock valued at $2,643,000 after buying an additional 1,321 shares in the last quarter. Ieq Capital LLC raised its position in shares of Zoetis by 23.9% in the 1st quarter. Ieq Capital LLC now owns 33,918 shares of the company's stock valued at $5,585,000 after buying an additional 6,541 shares in the last quarter. Nicolet Bankshares Inc. acquired a new position in shares of Zoetis in the 1st quarter valued at approximately $201,000. Finally, Samalin Investment Counsel LLC raised its position in shares of Zoetis by 9.0% in the 1st quarter. Samalin Investment Counsel LLC now owns 2,049 shares of the company's stock valued at $337,000 after buying an additional 169 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president directly owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Zoetis Trading Down 0.0%

ZTS opened at $155.12 on Wednesday. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market capitalization of $68.75 billion, a price-to-earnings ratio of 26.70, a PEG ratio of 2.49 and a beta of 0.88. The company's 50 day moving average price is $153.53 and its two-hundred day moving average price is $158.28.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period in the previous year, the firm posted $1.56 EPS. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ZTS shares. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. UBS Group decreased their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Finally, Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.